Sep 2026
Abstract B132: MAT2A inhibition enhances the anti-tumor efficacy of combined pan-RAS(ON) and PRMT5 inhibition in MTAP-deficient pancreatic tumors
The prevalence of both MTAP deletion and RAS mutations in pancreatic cancer is approximately 30∼40%. Dual inhibition of both pathways represents a promising therapeutic strategy. Preclinical and early clinical evidence supports the application of combined MTA-cooperative PRMT5 inhibitor and pan-RAS(ON) inhibitor...
Bin Liu, Lu Li, Yu-Lai Zhang et al.
· Cancer Research · 0 citations